Artivion, Inc. (AORT)

Artivion's stock has been influenced by several key events. The U.S. FDA approval of the NEXUS® Aortic Arch System led to a stock price increase, and provided Artivion with an option to acquire Endospan. The company participated in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference. The release of Fourth Quarter and Full Year 2025 Financial Results caused a stock decline despite revenue increase and EPS surpassing forecasts. Positive clinical data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials were presented at the 62nd Society of Thoracic Surgery Annual Meeting. Third Quarter 2025 Financial Results showed revenue and EBITDA growth, but the stock declined. Insiders sold a total of 133,043 shares in the past three months.

Artivion's demand for preservation services is subject to seasonal variations due to factors such as the quantity and type of incoming tissues, the yield of tissue through the preservation process, the timing of donor information receipt, staffing levels, the timing of tissue release for implantable status, and the demand for specific tissue types influenced by the number and kind of procedures being performed. Pressures from competing products or services can also affect demand.

Artivion, Inc. is a medical device company focused on solutions for cardiac and vascular surgeons, particularly in treating aortic diseases. It manufactures and distributes medical devices and implantable human tissues used in complex cardiac and vascular surgical procedures. The company's product portfolio includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, featuring products like BioGlue surgical adhesive, On-X aortic valve replacement, CryoValve SynerGraft Pulmonary Valve, and the NEXUS Aortic Arch System.

Artivion is headquartered in Kennesaw, Georgia, and has a global presence, marketing its products in over 100 countries. It operates across the United States, Europe, the Middle East, Africa, Asia Pacific, and Latin America, with North America generating the most revenue. The company has manufacturing facilities in Atlanta, Georgia, Austin, Texas, and Hechingen, Germany, along with sales and distribution offices throughout Europe, Asia, and South America.

Artivion's brand reputation has been positively impacted by the U.S. FDA approval of the NEXUS® Aortic Arch System and positive clinical data from the NEXUS TRIOMPHE and AMDS PERSEVERE Trials. However, a cybersecurity incident in 2024 has had a negative impact on the company's reputation.

Institutional investors hold a dominant share of Artivion's ownership, accounting for approximately 89.74% as of March 2025 and 92.12% as of Q1 2026. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, and Delaware Management Holdings, Inc. Company insiders own 7.60% of the stock.